Richard J. Benjamin, the Chief Medical Officer at Cerus Corporation (NASDAQ:CERS), sold 125,894 shares of common stock across three separate transactions executed between March 5 and March 9, 2026, totaling about $250,931. The sales spanned a price range of $1.8807 to $2.0626 per share.
Detailed filings show that on March 5 Benjamin sold 61,233 shares at a weighted average price of $2.0626 per share, with individual sale prices recorded between $2.02 and $2.17. The next day, March 6, he sold 24,235 shares at $2.0055 per share. On March 9 he sold 40,426 shares at a weighted average price of $1.8807, with the March 9 transactions executed in a range from $1.855 to $1.91.
The disclosures identify the March 5 and March 9 dispositions as having been made under a pre-arranged 10b5-1 trading plan. The March 6 sale, by contrast, was carried out to satisfy statutory tax withholding obligations and to pay brokerage fees associated with the vesting of restricted stock units.
In addition to the sales activity, the filings show that on March 5 Benjamin received 55,220 shares of Cerus common stock with no cash changing hands, a transaction that raised his total holdings to 1,004,995 shares at that time. After completing the March sales, his direct ownership stands at 879,101 shares.
Market context in the filings and accompanying notes highlights recent price movement for Cerus stock. The company’s shares have fallen 9.4% over the past week while registering a 64% gain over the prior six-month period. At the time of the analysis cited in the disclosure, the stock price was quoted at $1.93, and the equity was characterized as appearing undervalued relative to the platform’s valuation metrics, placing it among the platform’s list of most undervalued stocks. The disclosure also notes availability of a comprehensive Pro Research Report on CERS, which is one of more than 1,400 U.S. equities covered on that platform.
Cerus Corporation’s recent operational results are also reflected in the filings. For the fourth quarter of 2025 the company reported revenues of $233.8 million, a 16% increase compared with the same period a year earlier. Reported earnings per share were -$0.01, which the filings state was in line with market expectations. The revenue outperformance and the EPS result are presented in the disclosure as evidence of steady revenue growth and effective strategic initiatives, with the company described as having a solid footing in its current market environment.
The filings do not add commentary beyond the transaction mechanics, stock-performance figures and the company’s reported fourth-quarter financial results. They document the combination of planned-share disposals under a 10b5-1 arrangement, a tax-related sale tied to RSU vesting, and a simultaneous issuance of shares without a cash payment that altered the officer’s total holdings prior to the subsequent sales.